A5039491281- Lung Cancer Treatments and Mutations
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Lung Cancer Research Studies
- PI3K/AKT/mTOR signaling in cancer
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Advanced Breast Cancer Therapies
- Lung Cancer Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Estrogen and related hormone effects
- Head and Neck Cancer Studies
- Colorectal and Anal Carcinomas
- Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Melanoma and MAPK Pathways
- Gastrointestinal Tumor Research and Treatment
- Pain Management and Placebo Effect
- Colorectal Cancer Screening and Detection
- Cancer Treatment and Pharmacology
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Radiomics and Machine Learning in Medical Imaging
- Advances in Oncology and Radiotherapy
Instituto Alexander Fleming
2020-2025
Argentine Water and Sanitation (Argentina)
2021-2024
Fundación para la Investigación, Docencia y Prevención del Cáncer
2023
Institut Gustave Roussy
2019-2020
The generation of antibodies following exposure to therapeutic drugs has been widely studied, however in oncology, data relation their clinical relevance are limited. Antidrug (ADAs) can cause a decrease the amount drug available, resulting some cases decreased antitumor activity and consequent impact on outcomes. Several immunologic factors influence development ADAs, addition, sensitivity different testing methods used studies vary, representing an additional potential confounding factor....
In recent years, unprecedented benefits have been observed with the development of cyclin-dependent kinase (CDK) 4 and 6 inhibitors for treatment hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. However, there is scarce evidence their value in specific populations, such as patients carrying germline pathogenic variants DNA repair-related genes.We retrospectively studied efficacy CDK 4/6 plus endocrine therapy advanced Three cohorts were...
Abstract Background Programmed death ligand‐1 (PD‐L1) expression is a well‐known predictive biomarker of response to immune checkpoint blockade in non‐small cell lung cancer (NSCLC). However, there limited evidence the relationship between PD‐L1 expression, clinicopathological features, and their association with major driver mutations NSCLC patients Latin America. Methods This retrospective study included from Argentina advanced NSCLC, centralized evaluation concurrently genomic alterations...
Background/Objectives: BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There need for real-world data low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression free survival (PFS) overall (OS) the first-line setting, sequences of regimens. Methods: We retrospective analyze patients from ten oncology centers Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 July...
Background/Objectives: The BRAF-mutation is a poor prognostic factor in colorectal cancer (CRC). There need for real-world data low-middle-income countries regarding clinical characteristics, outcomes, and treatment strategies. This study aims to describe progression-free survival (PFS) the first- second-line setting sequences of regimens. Methods: We retrospectively analyze patients from ten oncology centers Argentina, diagnosed with BRAFV600E-mutated advanced CRC between January 2014 July...
e23135 Background: Cervical cancer represents a public health challenge in low and middle-income countries (LMIC). Instituto Misionero del Cancer (IMC) is tertiary center located Misiones, Argentina. In 2020, two policy implementations were introduced to improve the patient journey locally advanced cervical setting, including creation of navigation program brachytherapy unit province. Methods: A hospital-based registry comprising 951 patients diagnosed between January 2015 October 2024 was...
e13714 Background: Generative Artificial Intelligence (GenAI) is being rapidly integrated into clinical oncology practice. Recent publications highlight its potential benefits and risks in decision-making. Understanding stakeholders' perceptions low- middle-income countries (LMIC) critical for developing safe effective tools. Methods: A cross-sectional survey was conducted among volunteer participants attending the Argentinian Association of Clinical Oncology (AAOC) annual meeting 2024. The...
IntroductionDespite initial benefit, virtually all patients suffering from EGFR-mutant NSCLC experience acquired resistance to tyrosine kinase inhibitors (TKIs), driven by multiple mechanisms. Recent reports have identified oncogenic fusions as off-target mechanisms; however, these alterations been rarely investigated at EGFR TKIs progression.MethodsPatients with EGFR-mutated metastatic (N = 62) tissue and plasma biopsies TKI progression between January 2015 June 2019, a French hospital...
1056 Background: HER2-low expression, defined as HER2 immunohistochemistry (IHC) score of 1+ or 2+ with negative in situ hybridization assay (FISH), accounts for 50% breast cancers. There is limited and conflicting evidence regarding the efficacy cyclin-dependent kinase (CDK) 4 6 inhibitors patients ER+ tumors. This study aimed to investigate prognostic value expression ER+/HER2-negative advanced cancer treated CDK 4/6 inhibitors. Methods: We retrospectively selected consecutive plus...
e12633 Background: Triple negative breast cancer (TNBC) has been globally associated with a high risk of carrying pathogenic or likely (P/LP) variants in germline (BC) susceptibility genes (BCSG). Immunotherapy- based Neoadjuvant (pembro-NA) treatment is the preferred approach for localized, T2 node positive TNBC. To best our knowledge, information about peridiagnostic genetic counseling (PGC), status and their impact on patients (pts) undergoing this not reported yet. Our aim was to...
Breast metastasis from extra mammary malignancies is rare. An incidence of 0.2%-1.3% has been reported in the literature, including that different types malignant neoplasms.We present a case 29-year-old nonsmoking woman with breast lung adenocarcinoma. Computed tomography revealed atelectasis right middle lobe and ipsilateral pleural effusion. Additionally, on physical examination, small mass was noted her breast. The patient underwent bronchoscopy, needle thoracentesis, biopsy. Following...
The targeted therapy cetuximab [directed at the epidermal growth factor receptor (EGFR)] in combination with 5-fluorouracil and platinum-based chemotherapy (the EXTREME regimen) has shown substantial efficacy for patients recurrent or metastatic squamous cell carcinoma of head neck (R/M SCCHN). Thus, this scheme been established as preferred first-line option these patients. However, more recently, a new strategy combining platinum, taxanes, TPEx demonstrated similar favorable toxicity...